Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis

New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT

Detalles Bibliográficos
Autores principales: Glassberg, Marilyn K., Wijsenbeek, Marlies S., Gilberg, Frank, Petzinger, Ute, Kirchgaessler, Klaus-Uwe, Albera, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766683/
https://www.ncbi.nlm.nih.gov/pubmed/31164431
http://dx.doi.org/10.1183/13993003.00399-2019
_version_ 1783454758203293696
author Glassberg, Marilyn K.
Wijsenbeek, Marlies S.
Gilberg, Frank
Petzinger, Ute
Kirchgaessler, Klaus-Uwe
Albera, Carlo
author_facet Glassberg, Marilyn K.
Wijsenbeek, Marlies S.
Gilberg, Frank
Petzinger, Ute
Kirchgaessler, Klaus-Uwe
Albera, Carlo
author_sort Glassberg, Marilyn K.
collection PubMed
description New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT
format Online
Article
Text
id pubmed-6766683
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-67666832019-10-03 Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis Glassberg, Marilyn K. Wijsenbeek, Marlies S. Gilberg, Frank Petzinger, Ute Kirchgaessler, Klaus-Uwe Albera, Carlo Eur Respir J Agora New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT European Respiratory Society 2019-09-30 /pmc/articles/PMC6766683/ /pubmed/31164431 http://dx.doi.org/10.1183/13993003.00399-2019 Text en Copyright ©ERS 2019 http://creativecommons.org/licenses/by-nc/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Agora
Glassberg, Marilyn K.
Wijsenbeek, Marlies S.
Gilberg, Frank
Petzinger, Ute
Kirchgaessler, Klaus-Uwe
Albera, Carlo
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
title Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
title_full Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
title_fullStr Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
title_full_unstemmed Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
title_short Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
title_sort effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
topic Agora
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766683/
https://www.ncbi.nlm.nih.gov/pubmed/31164431
http://dx.doi.org/10.1183/13993003.00399-2019
work_keys_str_mv AT glassbergmarilynk effectofpirfenidoneonbreathlessnessinpatientswithidiopathicpulmonaryfibrosis
AT wijsenbeekmarliess effectofpirfenidoneonbreathlessnessinpatientswithidiopathicpulmonaryfibrosis
AT gilbergfrank effectofpirfenidoneonbreathlessnessinpatientswithidiopathicpulmonaryfibrosis
AT petzingerute effectofpirfenidoneonbreathlessnessinpatientswithidiopathicpulmonaryfibrosis
AT kirchgaesslerklausuwe effectofpirfenidoneonbreathlessnessinpatientswithidiopathicpulmonaryfibrosis
AT alberacarlo effectofpirfenidoneonbreathlessnessinpatientswithidiopathicpulmonaryfibrosis

Ejemplares similares